Table 3 Non-prescribed use of methadone, buprenorphine, and buprenorphine/naloxone in the study population
| Â | Non-prescribed use of methadone | Non-prescribed use of buprenorphine | Non-prescribed use of buprenorphine/naloxone |
|---|---|---|---|
Total | |||
 Whole population (411) | 87.8% | 80.5% | 50.6% |
Gender | |||
 Woman (104) | 85.6% | 75.0% | 54.1% |
 Man (307) | 88.6% | 82.4% | 43.0% |
 Chi-2 (P value) | 0.415 | 0.099 | 0.054 |
Country of birth | |||
 Sweden (333) | 88.9% | 82.6% | 53.5% |
 Other country (78) | 83.3% | 71.8% | 42.1% |
 Chi-2 (P value) | 0.177 | 0.030 | 0.073 |
Education | |||
 Comprehensive school (195) | 86.7% | 82.6% | 52.9% |
 High school or more (216) | 88.9% | 78.7% | 50.0% |
 Chi-2 (P value) | 0.491 | 0.324 | 0.563 |
Drug | |||
 Methadone (219) | 92.7% | 74.0% | 45.1% |
 Buprenorphine (112) | 81.3% | 87.5% | 49.5% |
 Buprenorphine/naloxone (80) | 83.8% | 88.8% | 70.9% |
 Chi-2 (P value) | 0.005 | 0.002 | 0.000 |
Treatment period, length of | |||
 Up to 1 year (138) | 90.6% | 88.4% | 65.9% |
 1–3 years (140) | 90.7% | 85.7% | 58.6% |
 More than 3 years (130) | 82.3% | 66.2% | 25.8% |
 Chi-2 (P value) | 0.054 | 0.000 | 0.000 |
Experience of involuntary discharge | |||
 No (262) | 85.9% | 80.2% | 52.3% |
 Yes (149) | 91.3% | 81.2% | 49.7% |
 Chi-2 (P value) | 0.108 | 0.795 | 0.606 |
City | |||
 Malmö (196) | 92.9% | 75.5% | 51.5% |
 Göteborg (118) | 81.4% | 88.1% | 49.1% |
 Lund (54) | 88.9% | 77.8% | 46.3% |
 Jönköping/Norrköping (43) | 81.4% | 86.0% | 63.4% |
 Chi-2 (P value) | 0.012 | 0.035 | 0.366 |
Interviewers | |||
 Researchers (280) | 88.2% | 78.6% | 49.1% |
 Privileged access interviewers (131) | 87.0% | 84.7% | 56.2% |
 Chi-2 (P value) | 0.731 | 0.142 | 0.184 |